Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    February 6, 2025
  • معلومة اضافية
    • Document Number:
      20250043003
    • Appl. No:
      18/895110
    • Application Filed:
      September 24, 2024
    • نبذة مختصرة :
      This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    • Claim:
      1.-10. (canceled)
    • Claim:
      11. An anti-CTLA-4 antibody comprising a heavy chain and a light chain, wherein (a) the heavy chain comprises the sequence set forth in SEQ ID NO: 18 and the light chain comprises the sequence set forth in SEQ ID NO: 11; (b) the heavy chain comprises the sequence set forth in SEQ ID NO: 16 and the light chain comprises the sequence set forth in SEQ ID NO: 10; or (c) the heavy chain comprises the sequence set forth in SEQ ID NO: 17 and the light chain comprises the sequence set forth in SEQ ID NO: 10.
    • Claim:
      12. The anti-CTLA-4 antibody of claim 11, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 18 and the light chain comprises the sequence set forth in SEQ ID NO: 11.
    • Claim:
      13. The anti-CTLA-4 antibody of claim 11, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 16 and the light chain comprises the sequence set forth in SEQ ID NO: 10.
    • Claim:
      14. The anti-CTLA-4 antibody of claim 11, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 17 and the light chain comprises the sequence set forth in SEQ ID NO: 10.
    • Claim:
      15. A method of cancer immunotherapy in a subject in need thereof, comprising administering the anti-CTLA-4 antibody of claim 11 to the subject.
    • Claim:
      16. The method of claim 15, wherein the anti-CTLA-4 antibody is administered with a second therapy.
    • Claim:
      17. The method of claim 16, wherein the second therapy is an anti-PD-1 antibody or an anti-PD-L1 antibody.
    • Claim:
      18. The method of claim 17, wherein antibody is an anti-PD-1 antibody and wherein the anti-PD-1 antibody is Nivolumab or Pembrolizmab.
    • Claim:
      19. A method of treating cancer in a subject in need thereof, comprising administering the anti-CTLA-4 antibody of claim 11 to the subject.
    • Current International Class:
      07
    • الرقم المعرف:
      edspap.20250043003